Basics Gilead Sciences, Inc. Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases. IPO Date: January 3, 1994 Sector: Healthcare Industry: Biotech Market Cap: $135.7B Activated in VL: True Average Daily Range Avg Daily Range: $0.73 | 1.13% Avg Daily Range (30 D): $1.54 | 1.50% Avg Daily Range (90 D): $1.44 | 1.38% Institutional Daily Volume Avg Daily Volume: 7.37M Avg Daily Volume (30 D): 6.77M Avg Daily Volume (90 D): 6.94M Trade Size Avg Trade Size (Sh.): 140 Avg Trade Size (Sh.) (30 D): 70 Avg Trade Size (Sh.) (90 D): 70 Institutional Trades Total Inst.Trades: 119,911 Avg Inst. Trade: $5.12M Avg Inst. Trade (30 D): $11.65M Avg Inst. Trade (90 D): $11.75M Avg Inst. Trade Volume: .12M Avg Inst. Trades (Per Day): 21 Market Closing Trades Avg Closing Trade: $54.35M Avg Closing Trade (30 D): $143.94M Avg Closing Trade (90 D): $159.01M Avg Closing Volume: 841.56K         News May 29, 2025 @ 2:58 PM Penicillin Market Research Report 2025 - Global $1... Source: Na May 9, 2025 @ 2:46 PM Merus annonce ses résultats financiers pour le ... Source: Merus N.V. Apr 28, 2025 @ 8:00 PM Nurix Therapeutics Presents Data at the AACR 2025 ... Source: N/A Apr 21, 2025 @ 6:49 PM Gilead Cancer Drug Combined With Merck's Drug Effe... Source: Vandana Singh Apr 17, 2025 @ 9:45 AM 2 High-Yielding ETFs Retirees Can Safely Build The... Source: David Jagielski Financials   TTM Q1 2025 Q4 2024 Basic EPS $4.77 $1.06 $1.42 Diluted EPS $4.75 $1.04 $1.42 Revenue $ 28.74B $ 6.67B $ 7.57B Gross Profit $ 22.5B $ 5.13B $ 5.99B Net Income / Loss $ 5.97B $ 1.32B $ 1.78B Operating Income / Loss $ 8.22B $ 2.24B $ 2.45B Cost of Revenue $ 6.24B $ 1.54B $ 1.58B Net Cash Flow $ 3.21B $ -2065M $ 4.96B PE Ratio 22.86     Splits Jan 28, 2013:   2:1 Jun 25, 2007:   2:1 Sep 07, 2004:   2:1 Mar 08, 2002:   2:1 Feb 22, 2001:   2:1